Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.

Publication ,  Journal Article
Watson, CH; Soo, L; Davidson, BA; Havrilesky, LJ; Lee, PS; McNally, LJ; Previs, RA; Secord, AA; Berchuck, A; Kauff, ND
Published in: Int J Gynecol Cancer
October 2020

OBJECTIVE: Limited information exists regarding risk reduction strategies for women with moderate and low penetrance ovarian cancer susceptibility mutations. We sought to assess current risk reduction practice patterns for carriers of these mutations through a survey of members of the Society of Gynecologic Oncology. METHODS: Society of Gynecologic Oncology members were emailed a survey consisting of two vignettes: (1) a 35-year-old premenopausal woman; (2) a 55-year-old postmenopausal woman with comorbidities. Each vignette contained sub-scenarios in which the patient had either a BRCA1 (relative risk (RR)=30-60), RAD51C (RR=5.0), or ATM (RR=1.5-2.0) mutation. Respondents were queried about their preferred management approach. Summary statistics were performed to describe results of the survey. We used χ2 testing for statistical analyses, comparing results according to mutation type and demographic information. RESULTS: A total of 193 (15%) of 1284 Society of Gynecologic Oncology members responded. For the premenopausal woman, 99%, 80%, and 40% would perform a risk reducing salpingo-oophorectomy prior to menopause in the setting of a BRCA1, RAD51C, and ATM mutation, respectively. For the postmenopausal woman, 98%, 85%, and 42% would proceed with risk reducing salpingo-oophorectomy in the setting of a BRCA1, RAD51C, and ATM mutation, respectively. Response distribution for carriers of RAD51C and ATM mutations were different from BRCA1 in both vignettes (p<0.001). CONCLUSIONS: Respondents were more likely to perform risk reducing salpingo-oophorectomy, in the setting of a BRCA1, RAD51C, and ATM mutation, earlier and more frequently in the setting of a BRCA1 mutation. However, there was a lack of consensus about management of the moderate and low penetrance mutations, suggesting that more data regarding age specific risks and appropriate risk reduction strategies for these alterations are needed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Gynecol Cancer

DOI

EISSN

1525-1438

Publication Date

October 2020

Volume

30

Issue

10

Start / End Page

1583 / 1588

Location

England

Related Subject Headings

  • Ubiquitin-Protein Ligases
  • Surveys and Questionnaires
  • Salpingo-oophorectomy
  • Risk Factors
  • Practice Patterns, Physicians'
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Gynecology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Watson, C. H., Soo, L., Davidson, B. A., Havrilesky, L. J., Lee, P. S., McNally, L. J., … Kauff, N. D. (2020). Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices. Int J Gynecol Cancer, 30(10), 1583–1588. https://doi.org/10.1136/ijgc-2020-001536
Watson, Catherine H., Lindsay Soo, Brittany A. Davidson, Laura J. Havrilesky, Paula S. Lee, Leah J. McNally, Rebecca A. Previs, Angeles Alvarez Secord, Andrew Berchuck, and Noah D. Kauff. “Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.Int J Gynecol Cancer 30, no. 10 (October 2020): 1583–88. https://doi.org/10.1136/ijgc-2020-001536.
Watson CH, Soo L, Davidson BA, Havrilesky LJ, Lee PS, McNally LJ, et al. Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices. Int J Gynecol Cancer. 2020 Oct;30(10):1583–8.
Watson, Catherine H., et al. “Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.Int J Gynecol Cancer, vol. 30, no. 10, Oct. 2020, pp. 1583–88. Pubmed, doi:10.1136/ijgc-2020-001536.
Watson CH, Soo L, Davidson BA, Havrilesky LJ, Lee PS, McNally LJ, Previs RA, Secord AA, Berchuck A, Kauff ND. Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices. Int J Gynecol Cancer. 2020 Oct;30(10):1583–1588.
Journal cover image

Published In

Int J Gynecol Cancer

DOI

EISSN

1525-1438

Publication Date

October 2020

Volume

30

Issue

10

Start / End Page

1583 / 1588

Location

England

Related Subject Headings

  • Ubiquitin-Protein Ligases
  • Surveys and Questionnaires
  • Salpingo-oophorectomy
  • Risk Factors
  • Practice Patterns, Physicians'
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Gynecology